Chief Medical Officer
Pharis Mohideen serves as Chief Medical Officer and is a member of DBV’s Executive Committee, responsible for continuing development efforts of the Company’s pipeline and bringing potentially innovative new treatments to patients, if approved. Dr. Mohideen brings nearly two decades of industry experience and a track record of multiple drug product approvals. Prior to joining DBV in July 2019, Dr. Mohideen served as Chief Medical Officer for Millendo Therapeutics, Inc., Vice President of Clinical Development at Shionogi Inc., and other clinical and medical leadership roles with Novartis International AG and Bristol Myers-Squibb. Prior to joining the pharmaceutical industry, Dr. Mohideen was an attending physician and assistant professor of medicine at the University of Hawaii, department of internal medicine and served as an investigator on multiple pharmaceutical-sponsored clinical trials.
Dr. Mohideen received his M.D., M.S. in human physiology and B.A. in biology from the University of Hawaii, as well as his M.S. in clinical investigation from Vanderbilt University.